Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
Open Access
- 26 August 2022
- journal article
- review article
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 9, 855-867
Abstract
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and one of the deadliest cancers worldwide. As opposed to the majority of patients with HCC, approximately 20– 30% of cases of non-alcoholic steatohepatitis (NASH)-derived HCC develop malignant tumours in the absence of liver cirrhosis. NASH is characterized by metabolic dysregulation, chronic inflammation and cell death in the liver, which provide a favorable setting for the transformation of inflammation into cancer. This review aims to describe the pathogenesis and the underlying mechanism of the transition from inflammation to cancer in NASH.Keywords
This publication has 138 references indexed in Scilit:
- The innate immune response during liver inflammation and metabolic diseaseTrends in Immunology, 2013
- Transgenic expression of human neutrophil peptide‐1 enhances hepatic fibrosis in mice fed a choline‐deficient, L‐amino acid–defined dietLiver International, 2013
- Risk factors for gastrointestinal bleeding associated with low-dose aspirinBest Practice & Research Clinical Gastroenterology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in miceLiver International, 2010
- Conventional DCs reduce liver ischemia/reperfusion injury in mice via IL-10 secretionJournal of Clinical Investigation, 2010
- Senescence of Activated Stellate Cells Limits Liver FibrosisCell, 2008
- Cancer-related inflammationNature, 2008
- Natural Killer Cells Ameliorate Liver Fibrosis by Killing Activated Stellate Cells in NKG2D-Dependent and Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Dependent MannersGastroenterology, 2006
- Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver diseaseHepatology, 2003